For years, cannabis operators have carried a tax burden unlike almost any other legal industry in America.
Under Section 280E of the Internal Revenue Code, cannabis businesses trafficking Schedule I substances were prohibited from deducting ordinary business expenses, forcing many operators to pay taxes on gross income instead of net profit. The result was a crushing financial reality that squeezed margins, stalled growth, and pushed some businesses toward insolvency.
Now, that landscape is beginning to shift.
The Trump administration’s April 23 order reclassifying state-licensed medical cannabis as a Schedule III substance marks one of the most financially significant policy changes the cannabis industry has ever seen. For medical operators, 280E relief is no longer theoretical… it is officially underway.
However, while the headlines focus on tax savings, the deeper story is far more complicated. The industry is entering a new phase where interpretation, compliance strategy, and IRS scrutiny may become just as important as the relief itself.
The End of Cannabis Rescheduling 280E… At Least for Medical Cannabis
The rescheduling order states that state-licensed medical cannabis businesses will no longer be subject to Section 280E restrictions. That means qualifying operators can begin deducting ordinary and necessary business expenses under Section 162, just like traditional businesses.
For many companies, this could immediately improve profitability, cash flow, and long-term viability.
The stakes are enormous. Industry analysts estimate cannabis operators have paid roughly $15 billion in excess taxes since 2018 due to 280E. Public cannabis companies alone reportedly owe or dispute more than $1.6 billion in tax liabilities tied to the provision.
Medical-only operators in states like Florida and Pennsylvania appear to have the clearest path forward. But businesses operating in both medical and adult-use markets are entering much murkier territory.
Because adult-use cannabis remains federally classified as Schedule I, 280E still technically applies to recreational sales. That creates immediate challenges around how businesses allocate expenses between medical and adult-use operations, including payroll, facilities, overhead, manufacturing costs, and shared administrative functions.
For vertically integrated operators, the accounting questions quickly become complex.
The Biggest Unanswered Question: Is Relief Retroactive?
The issue generating the most attention across the industry is whether cannabis businesses can recover taxes already paid under 280E.
The cannabis rescheduling order encourages the Treasury Department to “consider providing retrospective relief” for years in which businesses operated under qualifying medical marijuana licenses. However, the order stops short of guaranteeing refunds or amended return opportunities.
That ambiguity has created both optimism and uncertainty.
Some tax professionals argue that if cannabis now meets the criteria for Schedule III classification, then 280E arguably should never have applied in the first place. Others point out the practical challenge: the IRS may simply be unable – financially or administratively – to process billions of dollars in refunds across the industry.
Even if retroactive relief is permitted, timing matters.
Under federal tax law, refund claims are generally limited by statutes of limitation, typically three years from the filing date or two years from payment of the tax liability. For compliant operators that filed on time, some earlier tax years may already be closed.
Businesses that failed to preserve those statutes through protective filings or amended returns may lose access to potential refunds altogether.
A New Era of Tax Strategy and Risk
While the elimination of 280E represents a massive opportunity, it also introduces a completely new compliance environment for cannabis operators.
For years, cannabis taxation revolved around surviving under a regime of disallowance. Now the industry is shifting into a system based on interpretation, and interpretation creates risk.
Operators must now determine:
- What qualifies as an “ordinary and necessary” expense
- How shared expenses should be allocated
- Whether medical and adult-use activities can be separated cleanly
- How aggressive they should be with deductions and refund claims
- What positions can realistically withstand IRS examination
Those decisions will likely define the next chapter of cannabis tax litigation.
Many attorneys and accountants expect the industry to test aggressive legal theories in Tax Court, particularly around the argument that state-legal cannabis businesses never truly fit the intent or “meaning” of Schedule I trafficking under 280E.
At the same time, businesses pursuing aggressive tax positions may invite heightened IRS scrutiny in the years ahead.
R&D Credits Could Become the Industry’s Next Major Opportunity
One of the most overlooked benefits of cannabis rescheduling is access to federal research and development tax credits.
Cannabis operators engaged in cultivation innovation, genetics, extraction refinement, product formulation, or delivery system development may now have stronger footing to pursue R&D credits under Section 41.
That could create meaningful tax savings for companies investing heavily in product development and operational efficiency.
Still, tax professionals caution that R&D credits are already an area of intense IRS enforcement. Cannabis businesses entering this space without robust documentation or defensible methodologies could become prime audit targets.
In other words, the industry is not simply escaping one tax regime, it is entering another one that may require a far more sophisticated compliance strategy.
What Cannabis Businesses Should Be Doing Right Now
As operators wait for additional Treasury and IRS guidance, businesses should avoid assuming that cannabis rescheduling automatically eliminates tax risk.
This is the time for cannabis companies to:
- Review prior-year tax filings
- Evaluate statute-of-limitation deadlines
- Analyze medical vs. adult-use revenue allocations
- Assess whether amended returns or protective claims make sense
- Build defensible documentation systems
- Revisit entity structures and accounting methodologies
- Consult experienced cannabis tax and compliance professionals before taking aggressive positions
The operators that benefit most from this transition will likely be the ones that balance opportunity with defensibility.
The Bottom Line
Cannabis rescheduling may ultimately become one of the most transformative financial developments in modern industry history.
For medical cannabis operators, relief from 280E has the potential to unlock capital, improve margins, and stabilize businesses that have spent years operating under extraordinary tax pressure.
However, the next phase of the industry will not simply be about paying less tax. It will be about navigating a far more nuanced environment where accounting strategy, documentation, legal interpretation, and audit preparedness become central to survival.
The era of blanket tax punishment may be ending.
The era of cannabis tax scrutiny is just beginning.
Need help preparing your cannabis business for the post-280E era?
Canna Business Services helps cannabis operators navigate compliance, accounting, tax strategy, licensing, and operational risk management in an evolving regulatory environment.
